BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14561985)

  • 1. Localized radiation increases morbidity and mortality after TBI-containing autologous stem cell transplantation in patients with lymphoma.
    Emmanouilides C; Asuncion DJ; Wolf C; Scott S; Territo M
    Bone Marrow Transplant; 2003 Nov; 32(9):863-7. PubMed ID: 14561985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes.
    Chen CI; Abraham R; Tsang R; Crump M; Keating A; Stewart AK
    Bone Marrow Transplant; 2001 Jan; 27(2):177-82. PubMed ID: 11281387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.
    Hoppe BS; Moskowitz CH; Filippa DA; Moskowitz CS; Kewalramani T; Zelenetz AD; Yahalom J
    J Clin Oncol; 2008 Apr; 26(11):1858-64. PubMed ID: 18332466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combined high dose chemotherapy with autologous stem cell transplantation and total body radiotherapy for 32 malignant lymphoma patients].
    Wang H; Cui X; Shao Y
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):436-8. PubMed ID: 11810783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.
    Espigado I; Ríos E; Marín-Niebla A; Carmona M; Parody R; Pérez-Hurtado JM; Márquez FJ; Urbano-Ispizua A
    Transplant Proc; 2008 Nov; 40(9):3104-5. PubMed ID: 19010208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant.
    Wendland MM; Smith DC; Boucher KM; Asch JD; Pulsipher MA; Thomson JW; Shrieve DC; Gaffney DK
    Am J Clin Oncol; 2007 Apr; 30(2):156-62. PubMed ID: 17414465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
    Demirer T; Ayli M; Fen T; Ozcan M; Arat M; Buyukberber S; Arslan O; Gurman G; Akan H; Ilhan O
    Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease.
    Gabarre J; Marcelin AG; Azar N; Choquet S; Lévy V; Lévy Y; Tubiana R; Charlotte F; Norol F; Calvez V; Spina M; Vernant JP; Autran B; Leblond V
    Haematologica; 2004 Sep; 89(9):1100-8. PubMed ID: 15377471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group Study.
    Wirth A; Prince HM; Wolf M; Stone JM; Matthews J; Gibson J; Macleod C; Szer J; Grigg A; To B; Roos D; Schwarer AP; Davis S;
    Bone Marrow Transplant; 2005 Feb; 35(3):291-8. PubMed ID: 15558040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome.
    Gil L; Styczynski J; Komarnicki M
    Infection; 2007 Dec; 35(6):421-7. PubMed ID: 17926001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of malignant lymphoma by autologous hematopoietic stem cell transplantation combined with high dose radiotherapy and chemotherapy].
    Wang HQ; Cui XZ; Ren XB; Liu XM; Dai RZ; Zhang HL; Huang WY; Li W; Hao XS
    Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(11):948-51. PubMed ID: 12899794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma.
    Auner HW; Sill H; Mulabecirovic A; Linkesch W; Krause R
    Ann Hematol; 2002 Jul; 81(7):374-7. PubMed ID: 12185506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
    Ruiz-Soto R; Sergent G; Gisselbrecht C; Larghero J; Ertault M; Hennequin C; Manson J; de Kerviler E; Briere J; Mounier N
    Cancer; 2005 Dec; 104(12):2735-42. PubMed ID: 16284986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens.
    Salar A; Sierra J; Gandarillas M; Caballero MD; Marín J; Lahuerta JJ; García-Conde J; Arranz R; León A; Zuazu J; García-Laraña J; López-Guillermo A; Sanz MA; Grañena A; García JC; Conde E;
    Bone Marrow Transplant; 2001 Feb; 27(4):405-12. PubMed ID: 11313670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
    Yamane T; Hirose A; Nakajima Y; Nakane T; Koh H; Takeoka Y; Nakamae M; Yamamura R; Nakamae H; Nakao Y; Mugitani A; Yagi T; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):193-8. PubMed ID: 16484855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.
    Schetelig J; Fetscher S; Reichle A; Berdel WE; Beguin Y; Brunet S; Caballero D; Majolino I; Hagberg H; Johnsen HE; Kimby E; Montserrat E; Stewart D; Copplestone A; Rösler W; Pavel J; Kingreen D; Siegert W
    Haematologica; 2003 Nov; 88(11):1272-8. PubMed ID: 14607756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.